辛伐他汀治疗慢性阻塞性肺疾病合并代谢综合征患者的临床观察

目的:探讨辛伐他汀对慢性阻塞性肺疾病(COPD)合并代谢综合征患者的影响及临床价值。方法:将60例慢性阻塞性肺疾病合并代谢综合征患者随机分为辛伐他汀片治疗组和对照组,治疗组加用辛伐他汀片,治疗8周,于治疗前、后记录CAT得分、肺功能及血浆CRP、IL-8、IL-6、SOD的含量。结果:治疗后治疗组与治疗前比较CAT得分、CRP、IL-8、IL-6、SOD及血脂均前明显降低,差异有统计学意义(P<0.05);治疗后治疗组比对照组也有明显下降,差异有统计学意义(P<0.05);对照组治疗前后差异无统计学意义;治疗前后治疗组、对照组及两组间相比,FEVl、FEVl%差异无统计学意义(P>0.05)。结论:短期辛伐他汀治疗能改善COPD合并代谢综合征患者临床症状及降低CRP及炎症介质水平,但不能改善肺功能。

Simvastatin Therapy to Patients with Chronic Obstructive Pulmonary Disease Complicated with Metabolic Syndrome

Objective:To investigate the functional mechanism and impact of simvastatin inter vention in patients with chronic obstructive pulmonary disease complicated with metabolic syndrome.Methods:60 patients with chronic obstructive pulmonary disease with metabolic syndrome in sta tionary phase were randomly divided into intervention group and control group.The intervention group was given additional oral simvastatin 8 weeks for a cycle.CAT scores,pulmonary function and the levels of plasma C-reactive protein(CRP),interleukin-6(IL-6),interleukin-8(IL-8),SOD,blood lipids were recorded before and after treatment.Results:The CAT scores and CRP levels,inter leukin-6(IL-6),interleukin-8(IL-8),SOD,blood lipids decreased in interventiong group after treatment;compared the intervention group before and after treatment,and compared intervention group after treatment to control group after treatment,there was statisticat difference(P<0.05);in control group,compared before treatment to after treatment,there was no statistical difference.In comparison of FEV1,FEVl%,in intervention group and in control group before and after treatment,between the two groups also,there were no statistical differences(P > 0.05).Conclusion:Short term simvastatin treatment can improve the clinical symptoms and reduce the CRP and inflammatory mediators levels in patients with COPD,improve the quality of life,reduce the level of lipids.but can not improve lung function.